Frequency of 4336A>G in the patient cohorts
| Age (y) | Total No of samples | No (%) of samples with 4336A>G | Odds ratio | 95% CI | |
| Group 1 | |||||
| Sensorineural hearing loss | 44 ± 11 | 110 | 4 (3.6) | 6.0 | 1.3–27 |
| Migraine | 44 ± 7 | 42 | 2 (4.8) | 8.0 | 1.3–49 |
| Diabetes mellitus | 48 ± 10 | 122 | 1 (0.82) | 1.3 | 0.14–13 |
| Hypertrophic cardiomyopathy | 50 ± 14 | 20 | 1 (5.0) | 8.4 | 0.83–84 |
| Other phenotypes1-150 | 50 ± 15 | 281 | 0 | NA | NA |
| Controls | 41 ± 12 | 480 | 3 (0.63) | NA | NA |
| Group 2 | |||||
| Alzheimer's disease | 76 ± 9 | 175 | 3 (1.7) | 2.8 | 0.55–14 |
| Parkinson's disease | 69 ± 9 | 262 | 1 (0.38) | 0.61 | 0.06–5.9 |
| Non-AD dementia | 62 ± 12 | 60 | 1 (1.7) | 2.7 | 0.28–26 |
| Controls | 75 ± 6 | 107 | 0 | NA | NA |
Age denotes the age at the time of obtaining the blood sample. CI, confidence interval; Non-AD dementia, non-Alzheimer type dementia; NA, not applicable.
↵1-150 Other phenotypes include patients with epilepsy (n=165), ataxia (n=38), ophthalmoplegia (n=23), intracranial calcification (n=11), white matter disease (n=15), and occipital stroke (n=29).